|
MethoCult® products for human cells After more than 15 years on the market, we are changing the name of some of our MethoCult® media to make it easier for you to select the appropriate product for your needs. The media formulations and catalog numbers will remain unchanged. We will continue to provide you with the same quality media products which offer superior performance and lot-to-lot consistency.
The name change is being phased in as of October 15, 2009. Contact Technical Support (techsupport@STEMCELL.com) if you have any questions regarding the name change. product name | description | applications | | NEW! MethoCult® Express | "Complete" Medium with Cytokines (including EPO) | Total CFC in only 7 days | MethoCult® H4434 Classic
(MethoCult® GF H4434)
| "Complete" Medium with Cytokines
| CFU-E, BFU-E, CFU-GM, CFU-G, CFU-M, and CFU-GEMM | MethoCult® H4534 Classic without EPO
(MethoCult® GF H4534) | "Complete" Medium with Cytokines (- Epo) | CFU-GM, CFU-G, and CFU-M | | MethoCult® GF H4034 | "Complete" Medium with Cytokines (H4434 + G-CSF) | CFU-E, BFU-E, CFU-GM, CFU-G, CFU-M, and CFU-GEMM | MethoCult® Optimum without EPO
(MethoCult® GF H4035) | "Complete" Medium with Cytokines (H4534 + G-CSF) | CFU-GM, CFU-G, and CFU-M | MethoCult® H4435 Enriched
(MethoCult® GF+ H4435) | "Complete PLUS" Medium with Cytokines | CFU-E, BFU-E, CFU-GM, CFU-G, CFU-M, and CFU-GEMM; also CFC for LTC-IC | MethoCult® H4535 Enriched without EPO
(MethoCult® GF+ H4535) | "Complete PLUS" Medium with Cytokines (- Epo) | CFU-GM, CFU-G, and CFU-M | | MethoCult® SF H4436 | Serum-Free "Complete" Medium with Cytokines | CFU-E, BFU-E, CFU-GM, CFU-G, CFU-M, and CFU-GEMM | | MethoCult® SF H4536 | Serum-Free "Complete" Medium with Cytokines (- Epo) | CFU-GM, CFU-G, and CFU-M | | MethoCult® H4431 | "Complete" Medium with Agar-LCM and Epo | CFU-E, BFU-E, CFU-GM, CFU-G, CFU-M, and CFU-GEMM | | MethoCult® H4531 | "Complete" Medium with Agar-LCM without Epo | CFU-GM, CFU-G, and CFU-M; "epo-independent" erythroid progenitors | | MethoCult® H4433 | "Complete" Medium with PHA-LCM and Epo | CFU-E, BFU-E, CFU-GM, CFU-G, CFU-M, and CFU-GEMM | | MethoCult® H4533 | "Complete" Medium with PHA-LCM without Epo | CFU-GM, CFU-G, and CFU-M; "epo-independent" erythroid progenitors | | MethoCult® H4330 | Medium with Epo only | Allows addition of cytokines | | MethoCult® H4230 | Medium without Cytokines | -Epo; allows addition of cytokines | | MethoCult® SF H4236 | Serum-Free Medium without Cytokines | -Epo; allows addition of cytokines | | MethoCult® H4100 | "Base" Medium | Allows addition of sera, Epo, cytokines | | MethoCult® H4001 | Medium without 2-ME
(with GM-CSF) | CFU-GM, CFU-G, and CFU-M
(in vitro drug sensitivity testing) | | MethoCult® Z4003 | Medium without 2-ME or cytokines | Canine, Rat, Mouse and Human CFU-GM, CFU-G, and CFU-M (in vitro drug sensitivity testing) | | Colony Assay "Starter" Kit | Contains either H4034, H4434 or H4534 | |
Please click here for CE Marked IVD MethoCult® products available in the European Union. Also Available: MethoCult® media for mouse, rat, and non-human primate cells. Contact us for custom formulations.
Click here to view cord blood colony images and tips for identification.
ADVANTAGES OF MethoCult® MEDIUM FROM STEMCELL TECHNOLOGIES |
Twenty-five years of expertise in manufacturing MethoCult® methylcellulose-based medium
|
Quality Control performance testing to ensure low lot-to-lot variability
|
Extensively prescreened components
|
Aseptically manufactured and sterility tested
|
Flexible format - Most formulations are available in bottles or racks of 24 tubes
|
Custom formulations and sizes available upon request
|
|
Applications of MethoCult® for human cells
Support patient diagnosis, prognosis and treatment in a clinical hematology lab1-7 Support the evaluation of donor samples (including CB) for stem cell transplants8-10 Quality control cryopreservation, cell processing and ex vivo manipulation such as T-cell depletion11-18 Study effects of cytokines, growth factors, hormones or mimetics on hematopoietic progenitors19-23 Perform toxicity testing or drug screening assays24-27
References
1. Chervenick PA, Blood 41: 67-71, 1973
2. Douay L et al., Exp Hematol 14: 358-365, 1986
3. Haas R et al., Blood 85: 3754-3761, 1995
4. Jagannath S et al., Blood 80: 1666-1672, 1992
5. Marit G et al., Leukemia 12: 1447-1456, 1998
6. Migliaccio AR et al., Blood 96: 2717-2722, 2000
7. Sagaster V et al., Haematologica 88: 1204-1212, 2003
8. Iori AP et al., Bone Marrow Transplant 33: 1097-1105, 2004
9. Spitzer G et al., Blood 55: 317-323, 1980
10. Yoo KH et al., Bone Marrow Transplant 39: 515-521, 2007
11. Alonso JM 3rd et al., Cytotherapy 3: 429-433, 2001
12. Broxmeyer HE et al., Proc Natl Acad Sci USA 100: 645-650, 2003
13. Guimond M et al., Blood 100: 375-382, 2002
14. Itoh T et al., Transfusion 43: 1303-1308, 2003
15. Koliakos G et al., Cytotherapy 9: 654-659, 2007
16. Rubinstein P et al., Proc Natl Acad Sci USA 92: 10119-10122, 1995
17. Slaper-Cortenbach ICM et al., Rheumatology 38: 751-754, 1999
18. Timeus F et al., Haematologica 88: 74-79, 2003
19. Balducci E et al., Stem Cells 21: 33-40, 2003
20. Frostad S et al., Stem Cells 16: 334-342, 1998
21. Mayani H et al., Blood 81: 3252-3258, 1993
22. Qureshi SA et al., Proc Natl Acad Sci USA 96: 12156-12161, 1999
23. Schwartz GN et al., Stem Cells 14: 337-350, 1996
24. Gribaldo L et al., Exp Hematol 27: 1593-1598, 1999
25. Pessina A et al., Toxicol Sci 75: 355-367, 2003
26. Pessina A et al., Toxicol In Vitro 15: 729-740, 2001
27. Volpe DA et al., Toxicol In Vitro 17: 271-277, 2003
FOR RESEARCH USE ONLY
|
